Mar 07, 2023 / 07:50PM GMT
Philip M. Nadeau - TD Cowen, Research Division - MD & Senior Research Analyst
[TD Cowen's 43rd] Annual Health Care Conference. I'm Phil Nadeau, one of Cowen's biotech analysts and it's my pleasure to do a fireside chat one of the bellwethers of the industry, Vertex. Happy to have with us today, president and CEO, Reshma Kewalramani; and Charlie Wagner, CFO.
Reshma, I'll hand it to you first for some opening remarks.
Reshma Kewalramani - Vertex Pharmaceuticals Incorporated - CEO, President & Director
Sure. Phil, thank you so much for having us here. it's wonderful to see all of you in person in our home city of Boston.
To start with, maybe I'll just give you a little bit of a flavor for where Vertex is today, touch on a few of our programs and then Phil, we can go into any one of those that you'd like to. It is an extraordinarily exciting time for us at Vertex. Having now brought 4 CF medicines to market and transformed that disease. The growth in our CF franchise has transformed Vertex. We are now involved in 8 disease areas, including
Vertex Pharmaceuticals Inc at Cowen Health Care Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers